Insys Therapeutics Company Profile (NASDAQ:INSY)

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INSY
  • CUSIP: N/A
  • Web: www.insysrx.com
Capitalization:
  • Market Cap: $864.06 million
  • Outstanding Shares: 72,125,000
Average Prices:
  • 50 Day Moving Avg: $12.42
  • 200 Day Moving Avg: $11.43
  • 52 Week Range: $8.70 - $19.96
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -27.70
  • P/E Growth: -0.92
Sales & Book Value:
  • Annual Revenue: $217.82 million
  • Price / Sales: 4.04
  • Book Value: $3.71 per share
  • Price / Book: 3.29
Profitability:
  • EBIDTA: $3.16 million
  • Net Margins: -2.64%
  • Return on Equity: -0.97%
  • Return on Assets: -0.75%
Debt:
  • Current Ratio: 3.18%
  • Quick Ratio: 2.84%
Misc:
  • Average Volume: 590,146 shs.
  • Beta: 0.88
  • Short Ratio: 13.58
 
Frequently Asked Questions for Insys Therapeutics (NASDAQ:INSY)

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics shares split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were payable to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics, Inc. (NASDAQ:INSY) released its earnings results on Tuesday, May, 9th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $35.92 million for the quarter, compared to analyst estimates of $37.78 million. Insys Therapeutics had a negative return on equity of 0.97% and a negative net margin of 2.64%. The firm's revenue for the quarter was down 40.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.11 EPS. View Insys Therapeutics' Earnings History.

Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2017?

4 analysts have issued 12 month price objectives for Insys Therapeutics' stock. Their predictions range from $10.00 to $16.00. On average, they expect Insys Therapeutics' stock price to reach $13.33 in the next twelve months. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:

  • Steven J. Meyer, Chairman of the Board
  • Saeed Motahari, President, Chief Executive Officer, Director
  • Darryl S. Baker, Chief Financial Officer
  • Franc Del Fosse, General Counsel, Corporate Secretary
  • Michael L. Babich, Director
  • John N. Kapoor Ph.D., Director
  • Rohit Vishnoi, Director
  • Patrick P. Fourteau, Independent Director
  • Pierre Lapalme, Independent Director

Who owns Insys Therapeutics stock?

Insys Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Eqis Capital Management Inc. (0.09%). Company insiders that own Insys Therapeutics stock include Daniel Brennan, John N Kapoor Trust Dated Sept, Patrick Fourteau, Rohit Vishnoi, Saeed Motahari, Steven J Meyer and Theodore H Stanley. View Institutional Ownership Trends for Insys Therapeutics.

Who bought Insys Therapeutics stock? Who is buying Insys Therapeutics stock?

Insys Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy Insys Therapeutics stock?

Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of Insys Therapeutics stock can currently be purchased for approximately $12.19.


MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.33 (9.38% upside)

Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/4/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
6/9/2017Jefferies Group LLCReiterated RatingBuy$14.00LowView Rating Details
6/3/2017Royal Bank Of CanadaSet Price TargetBuy$16.00HighView Rating Details
5/10/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$20.00 -> $10.00LowView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00N/AView Rating Details
(Data available from 7/25/2015 forward)

Earnings

Earnings History for Insys Therapeutics (NASDAQ:INSY)
Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)
Earnings History by Quarter for Insys Therapeutics (NASDAQ INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016$0.00$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
Current Year EPS Consensus Estimate: $-0.53 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Dividends

Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Insys Therapeutics (NASDAQ:INSY)
Insider Ownership Percentage: 67.90%
Institutional Ownership Percentage: 28.18%
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2017Saeed MotahariCEOBuy5,400$11.10$59,940.00View SEC Filing  
6/1/2017Rohit VishnoiDirectorBuy4,000$14.14$56,560.00View SEC Filing  
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.00View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.00View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.00View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Insys Therapeutics (NASDAQ:INSY)
Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
Source:
DateHeadline
reuters.com logoFBI seizes records tied to Insys-paid doctor in Kansas - Reuters
www.reuters.com - July 21 at 9:15 PM
globenewswire.com logoInsys Therapeutics to Report Second Quarter 2017 Results on August 3, 2017 - GlobeNewswire (press release)
globenewswire.com - July 21 at 4:47 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (NASDAQ:INSY) Expected to Post Quarterly Sales of $36.89 Million
www.americanbankingnews.com - July 20 at 11:13 AM
feeds.benzinga.com logoInsys Therapeutics to Report Second Quarter 2017 Results on August 3, 2017
feeds.benzinga.com - July 20 at 8:14 AM
streetinsider.com logoInsys Therapeutics (INSY) Appoints Andrew Long as CFO
www.streetinsider.com - July 19 at 3:43 AM
finance.yahoo.com logoInsys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer
finance.yahoo.com - July 19 at 3:43 AM
nasdaq.com logoInsys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer - Nasdaq
www.nasdaq.com - July 18 at 10:39 PM
finance.yahoo.com logoETFs with exposure to INSYS Therapeutics, Inc. : July 18, 2017
finance.yahoo.com - July 18 at 10:39 PM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - July 18 at 8:20 PM
nasdaq.com logoInsys Therapeutics, Inc. Releases Statement on Payor Interactions ... - Nasdaq
www.nasdaq.com - July 18 at 2:25 AM
finance.yahoo.com logoINSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : July 17, 2017
finance.yahoo.com - July 18 at 2:25 AM
reuters.com logoBRIEF-Insys Therapeutics Inc releases statement on payor interactions
www.reuters.com - July 17 at 8:24 AM
finance.yahoo.com logoInsys Therapeutics, Inc. Releases Statement on Payor Interactions
finance.yahoo.com - July 17 at 8:24 AM
seekingalpha.com logoInsys: Anthem Lawsuit Paves The Road For An Equity Raise And Continued Downside Pressure On The Stock
seekingalpha.com - July 16 at 12:01 PM
finance.yahoo.com logoHere's the spiel one drug company allegedly used to push its opioids on Americans
finance.yahoo.com - July 15 at 2:25 AM
finance.yahoo.com logoCannabis Industry Weekly Recap 7/14/2017
finance.yahoo.com - July 15 at 2:25 AM
reuters.com logoAnthem files lawsuit against Insys Therapeutics - Reuters
www.reuters.com - July 14 at 3:57 AM
reuters.com logoUPDATE 1-Ex-Insys CEO's wife pleads guilty in US to opioid kickback scheme - Reuters
www.reuters.com - July 13 at 3:20 AM
reuters.com logoEx-Insys saleswomen plead guilty in US to drug kickback schemes - Reuters
www.reuters.com - July 13 at 3:20 AM
News IconOpioid drugmaker Insys sees guilty pleas and Justice Department ... - Business Insider
www.businessinsider.com - July 13 at 3:20 AM
fool.com logoWhy Barnes & Noble Education, MSC Industrial Direct, and Insys ... - Motley Fool
www.fool.com - July 13 at 3:20 AM
wsj.com logoEx-Insys Saleswomen Plead Guilty in Opioid Prescription Kickback Schemes
www.wsj.com - July 11 at 11:58 PM
finance.yahoo.com logoEx-Insys CEO's wife pleads guilty in U.S. to opioid kickback scheme
finance.yahoo.com - July 11 at 11:58 PM
finance.yahoo.com logoEx-Insys saleswomen plead guilty in U.S. to drug kickback schemes
finance.yahoo.com - July 11 at 11:58 PM
finance.yahoo.com logo[$$] Ex-Insys Saleswomen Plead Guilty in Opioid Prescription Kickback Schemes
finance.yahoo.com - July 11 at 11:58 PM
reuters.com logoEx-Insys employee in US kickback case loses fight to smoke pot - Reuters
www.reuters.com - July 10 at 7:52 PM
finance.yahoo.com logoEx-Insys employee in U.S. kickback case loses fight to smoke pot
finance.yahoo.com - July 10 at 7:52 PM
americanbankingnews.com logoInsys Therapeutics, Inc. (NASDAQ:INSY) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 10 at 9:50 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (NASDAQ:INSY) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - July 9 at 1:40 PM
finance.yahoo.com logoWill These Be the Top Marijuana Stocks to Own in 2018?
finance.yahoo.com - July 9 at 9:26 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (NASDAQ:INSY) Raised to Buy at BidaskClub
www.americanbankingnews.com - July 8 at 6:32 PM
finance.yahoo.com logoWhy This Marijuana Stock Dropped 11% in June
finance.yahoo.com - July 8 at 11:46 AM
finance.yahoo.com logoETFs with exposure to INSYS Therapeutics, Inc. : July 7, 2017
finance.yahoo.com - July 8 at 11:46 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 4 at 9:42 PM
finance.yahoo.com logoETFs with exposure to INSYS Therapeutics, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 7:45 PM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) Expected to Post Quarterly Sales of $36.56 Million
www.americanbankingnews.com - June 24 at 8:48 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) Expected to Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - June 22 at 4:42 PM
cnbc.com logoFormer Insys employee pleads guilty in US opioid drug probe - CNBC
www.cnbc.com - June 21 at 3:38 PM
globenewswire.com logoInsys Therapeutics Hires Four Key Pharmaceutical Industry ... - GlobeNewswire (press release)
globenewswire.com - June 21 at 4:53 AM
finance.yahoo.com logoEx-Insys employee pleads guilty in U.S. opioid drug probe
finance.yahoo.com - June 19 at 4:54 PM
finance.yahoo.com logoWill SYNDROS Potential Replace SUBSYS Challenges
finance.yahoo.com - June 16 at 6:48 PM
finance.yahoo.com logoINSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 6:48 PM
finance.yahoo.com logoOpioid Marketing Under Bipartisan Investigation
finance.yahoo.com - June 16 at 5:37 AM
finance.yahoo.com logoETFs with exposure to INSYS Therapeutics, Inc. : June 15, 2017
finance.yahoo.com - June 16 at 5:37 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) CEO Saeed Motahari Buys 5,400 Shares
www.americanbankingnews.com - June 14 at 8:18 PM
seekingalpha.com logoInsys Therapeutics' Undervalued Cannabis Pipeline - Seeking Alpha
seekingalpha.com - June 14 at 7:55 PM
seekingalpha.com logoInsys: Continued Subsys Fallout As Endo's Painkiller Pulled By FDA - Seeking Alpha
seekingalpha.com - June 12 at 6:33 PM
finance.yahoo.com logoINSYS Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : INSY-US : June 12, 2017
finance.yahoo.com - June 12 at 6:33 PM
seekingalpha.com logoINSYS Therapeutics (INSY) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 10 at 10:54 PM
finance.yahoo.com logoDepomed, Insys Shares Down After FDA Decision on Endo's Opana ER
finance.yahoo.com - June 9 at 8:23 PM

Social

Chart

Insys Therapeutics (INSY) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff